Frank Kalkbrenner
Director/Board Member at Hookipa Biotech AG
Network origin in Frank Kalkbrenner first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.
19
| Subsidiary | Medical Specialties | 19 |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts.
17
| Operating Division | Investment Managers | 17 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.
15
| Holding Company | Biotechnology | 15 |
Acousia Therapeutics GmbH
 Acousia Therapeutics GmbH BiotechnologyHealth Technology Acousia Therapeutics GmbH identifies small molecules for treatment of hearing loss. The firm develops drugs for local application, which will protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons. It also develops small molecule compounds that trigger regeneration of sensory hair cells and therefore allow casual treatment of sensorineural hearing loss in patients who already lost their hair cells years ago. The company was founded by Hubert Löwenheim and Karl-Heinz Wiesmüller in 2012 and is headquartered in Tübingen, Germany.
9
| Holding Company | Biotechnology | 9 |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom.
7
| Holding Company | Miscellaneous Commercial Services | 7 |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.
4
| Subsidiary | Medical Specialties | 4 |
T3 Pharmaceuticals AG
 T3 Pharmaceuticals AG BiotechnologyHealth Technology T3 Pharmaceuticals AG provides medicines and treatment for cancer patient. The company was founded in May 2015 by Simon J. Ittig, Christoph A. Kasper, Marlise Amstutz and Helmut H. Kessmann and is headquartered in Basel, Switzerland.
4
| Subsidiary | Biotechnology | 4 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.
4
| Subsidiary | Biotechnology | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Frank Kalkbrenner via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HOOKIPA PHARMA INC. | Biotechnology | Director/Board Member Chief Executive Officer Chairman Founder Director/Board Member Director/Board Member Founder Founder Director/Board Member Founder Founder | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Basel | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| Ghent University | College/University | Corporate Officer/Principal Graduate Degree Doctorate Degree | |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder President Chief Tech/Sci/R&D Officer | |
| University College London | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| University of Geneva | College/University | Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal | |
Participatiemaatschappij Vlaanderen NV
 Participatiemaatschappij Vlaanderen NV Investment ManagersFinance Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member Director/Board Member | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Founder | |
| CELYAD ONCOLOGY SA | Biotechnology | Director/Board Member Corporate Officer/Principal | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Vlerick Leuven Gent Management School | College/University | Masters Business Admin Masters Business Admin | |
| University of Hohenheim | College/University | Doctorate Degree Undergraduate Degree | |
| ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
EQT Life Sciences Group BV
 EQT Life Sciences Group BV Investment ManagersFinance EQT Life Sciences Group BV (EQT Life Sciences) is a venture capital firm, a subsidiary of EQT AB founded in 2022 after the acquisition of LSP by EQT. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor | |
Cell Therapy Catapult Ltd.
 Cell Therapy Catapult Ltd. BiotechnologyHealth Technology Cell Therapy Catapult Ltd. engages in the development, delivery, and commercializing of cell and gene therapy. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
TACALYX GmbH
 TACALYX GmbH Miscellaneous Commercial ServicesCommercial Services TACALYX GmbH engages in the discovery and development of Tumor Associated Carbohydrate Antigenantibodies to treat cancer. The company was founded by Peter Sondermann, Peter H. Seeberger, and Oren Moscovitz and is headquartered in Berlin, Germany. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Abalos Therapeutics GmbH
 Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Biotechnology | Chief Executive Officer Director/Board Member | |
Sanofi Pasteur, Inc.
 Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. | Pharmaceuticals: Major | President Chief Tech/Sci/R&D Officer | |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Founder | |
| UNIQURE N.V. | Biotechnology | Chief Executive Officer Founder | |
| Harvard Business School | College/University | Undergraduate Degree Masters Business Admin | |
| Karolinska Institutet | College/University | Doctorate Degree Corporate Officer/Principal | |
GeneSpire Srl
 GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Biotechnology | Chairman Director/Board Member | |
| University of Utrecht | College/University | Corporate Officer/Principal Graduate Degree | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Private Equity Investor Private Equity Investor | |
Phenex Pharmaceuticals AG
 Phenex Pharmaceuticals AG Pharmaceuticals: GenericHealth Technology Phenex Pharmaceuticals AG engages in the research and development of small molecule drugs focusing on the identification and analysis of selective drug candidates that target nuclear receptors. It also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other life science industries. The company was founded by Claus Kremoser in 2002 and is headquartered in Ludwigshafen, Germany. | Pharmaceuticals: Generic | Chairman Founder | |
Acambis Plc
 Acambis Plc BiotechnologyHealth Technology Acambis Plc develops biopharmaceutical products and vaccines. It offers ACAM2000, a smallpox vaccine for emergency-use stockpiling; and ChimeriVax-JE, a single-dose Japanese encephalitis vaccine for endemic markets and travelers. Its products in pipeline include ChimeriVax-JE, ChimeriVax-West Nile, and ChimeriVax-Dengue. The company was founded in 1992 and is headquartered in Cambridge, UK. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| SPEXIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
SpliceBio SL
 SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member Director/Board Member | |
AgomAb Therapeutics NV
 AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| MODERNA, INC. | Biotechnology | Founder President | |
Bodyport, Inc.
 Bodyport, Inc. Packaged SoftwareTechnology Services Bodyport, Inc. manufactures sensor fitted weighing scales. It offers scale that measures weight like others do, but also measures blood pressure, heart rate, heart rate variability, and arterial stiffness through a user's feet. The company was founded by Corey Centen and Sarah Smith and is headquartered in San Francisco, CA. | Packaged Software | Director/Board Member Director/Board Member | |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Doctorate Degree | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| Radboud University Nijmegen | College/University | Undergraduate Degree Doctorate Degree | |
NBE-Therapeutics AG
 NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member Director/Board Member |
Statistics
International
| United States | 13 |
| Belgium | 10 |
| Switzerland | 8 |
| Netherlands | 8 |
| Germany | 7 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 13 |
| Finance | 6 |
| Commercial Services | 5 |
| Health Services | 2 |
Operational
| Director/Board Member | 316 |
| Corporate Officer/Principal | 103 |
| Founder | 49 |
| Chairman | 49 |
| Private Equity Investor | 49 |
Most connected contacts
| Insiders | |
|---|---|
| Marijn Dekkers | 35 |
| Graziano Seghezzi | 26 |
| Prabhavathi Fernandes | 23 |
| Vincent Ossipow | 22 |
| John Paul de Koning | 21 |
| Karin Hehenberger | 21 |
| Gérard Vaillant | 20 |
| Michael Kelly | 19 |
| Debasish Francois Roychowdhury | 18 |
| Claire Brown | 17 |
| Sander J. van Deventer | 17 |
| Alexandra Tolia | 15 |
| Vincent Brichard | 15 |
| Jan van de Winkel | 15 |
| Graeme Martin | 15 |
- Stock Market
- Insiders
- Frank Kalkbrenner
- Company connections
